Drug firm Divis Laboratories today said the US health regulator has conducted a successful inspection of its Unit-2 facility at Visakhapatnam this month.
"The company has had a successful inspection by the United States Food and Drug Administration (USFDA) for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February, 2016 with no observations," Divis Laboratories said in a filing to BSE.
Shares of Divis Laboratories today closed at Rs 993.90 on BSE, up 1.91 per cent from the previous close.
